BASILEA N/ CH0011432447 /
| 10/3/2023 5:30:13 PM | Chg. -1.300 | Volume | Bid5:40:00 PM | Ask5:40:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 40.800CHF | -3.09% | 19,170 Turnover: 790,946.775 |
40.600Bid Size: 400 | 41.200Ask Size: 400 | 534.34 mill.CHF | - | 40.00 |
GlobeNewswire
3/8/2022
Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at...
GlobeNewswire
2/15/2022
Basilea to become a leading anti-infectives company backed by strong financial results 2021
GlobeNewswire
1/24/2022
Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications fr...
GlobeNewswire
1/13/2022
Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in Chi...
GlobeNewswire
1/11/2022
Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobipr...
GlobeNewswire
1/10/2022
Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
GlobeNewswire
1/7/2022
Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales mileston...
GlobeNewswire
12/21/2021
Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavu...
GlobeNewswire
12/17/2021
Basilea announces FDA approval of Investigational New Drug application for novel oncology drug candi...
GlobeNewswire
12/8/2021
Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone pa...
GlobeNewswire
11/16/2021
Basilea announces submission of Investigational New Drug application for novel oncology drug candida...
GlobeNewswire
10/11/2021
Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor mo...
GlobeNewswire
9/30/2021
Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of i...
GlobeNewswire
9/17/2021
Basilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-pos...
GlobeNewswire
8/17/2021
Basilea reports strong financial results for half-year 2021 with significantly increased cash flow f...
GlobeNewswire
8/16/2021
Basilea awarded additional USD 4.3 million by BARDA to support phase 3 development of ceftobiprole
GlobeNewswire
7/29/2021
Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of mali...
GlobeNewswire
7/26/2021
Basilea’s partner Asahi Kasei Pharma prepares NDA filing for the marketing authorization of isavucon...
GlobeNewswire
7/14/2021
Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) cove...
GlobeNewswire
6/7/2021
Basilea reports new prevalence data for EB1, a potential response-predictive biomarker for lisavanbu...
GlobeNewswire
5/31/2021
Basilea provides updates on efficacy data with derazantinib in bile duct cancer and on ongoing clini...
GlobeNewswire
5/19/2021
Basilea awarded CARB-X grant of up to USD 2.7 million to develop novel-class antibiotic